Determinants of tumor sensitivity to EGFR-targeted antibodies This project has focused on understanding the critical structural determinants of anti-tumor antibodies that promote tumor-specific, antibody-dependent cellular cytotoxicity (ADCC), defining the antibody structural features and treatment strategies that maximize ADCC and promote the induction of adaptive immunity. Recently, our focus has shifted to analyzing the tumor-intrinsic factors that sensitize tumor cells to antibody therapy. We hypothesized that siRNA screening focused on genes functionally linked to the EGFR signaling pathway would identify tumor-intrinsic genes that regulate the tumor cell response to antigen engagement and ADCC promotion by monoclonal antibodies. To test this hypothesis, we have developed and applied a customized 638-element siRNA library containing genes known to functionally interact with EGFR (the EGFR functional "interactome"). Using this library, we identified a restricted number of genes whose knockdown selectively alters tumor cell viability in the presence of panitumumab and other EGFR inhibitors. We have identified "clusters" of genes known to act together in discrete sub-pathways, which we predict will be important for regulation of EGFR family-directed signaling inhibition and ADCC. This project will dissect immunologic and signaling mechanism contributions to antibody efficacy, and then identify efficacy-sensitizing genes for signaling and ADCC.
Specific Aim 1 is to determine the roles of signaling inhibition and ADCC in mediating the efficacy of EGFR pathway-directed monoclonal antibodies.
Specific Aim 2 is to define the elements of the EGFR interactome that modify target cell death in response to antibody engagement using cell culture-based functional tests to confirm the mechanisms by which siRNA depletion enhances tumor cell killing and in vivo models. In vitro and in vivo validation studies will identify new antibody-based therapy combinations. These studies will also identify those genes that regulate cellular sensitivity to EGFR inhibition and ADCC sensitivity.
Specific Aim 3 is to determine the influence of mutations in critical signaling genes on EGFR antibody-targeted cytotoxicity. The completion of these aims will yield an improved understanding of the critical mechanisms that underlie successful antibody therapy, and will form the basis for future monoclonal antibody treatment strategies.
Our laboratory aims to improve antibody therapy of cancer. We have been interested in understanding how the structures of anti-tumor antibodies influence their abilities to stimulate immune-mediated tumor destruction. Here, we propose to analyze how tumor properties sensitize tumor cells to antibody therapy. We tested the concept that the selective knockdown of genes in the epidermal growth factor receptor (EGFR) signaling pathway would identify tumor-intrinsic genes that regulate the tumor cell response to antibody engagement and immune activation by cetuximab, and other monoclonal antibodies. To accomplish this, we developed and applied a customized 638-element siRNA library containing genes known to interact with EGFR (the EGFR functional "interactome"). Using this library, we have identified a restricted number of genes that that can be knocked down to sensitize tumors to destruction by EGFR inhibitors. We will use this technology to dissect the relative contributions of immune and signaling mechanisms to antibody related treatment benefits. Specific genes that regulate each of these mechanisms will be identified and exploited to improve antibody therapy.
|Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93|
|Surana, Rishi; Wang, Shangzi; Xu, Wei et al. (2014) IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model. Cancer Immunol Res 2:1103-12|
|Gleason, Michelle K; Ross, Julie A; Warlick, Erica D et al. (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016-26|
|Shivapurkar, Narayan; Weiner, Louis M; Marshall, John L et al. (2014) Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One 9:e84686|
|Murray, Joseph C; Aldeghaither, Dalal; Wang, Shangzi et al. (2014) c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res 2:1186-98|
|Smaglo, Brandon G; Aldeghaither, Dalal; Weiner, Louis M (2014) The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol 11:637-48|
|Mehra, Ranee; Serebriiskii, Ilya G; Burtness, Barbara et al. (2013) Aurora kinases in head and neck cancer. Lancet Oncol 14:e425-35|
|Sukhanova, Anna; Gorin, Andrey; Serebriiskii, Ilya G et al. (2013) Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov 3:96-111|
|Weiner, Louis M; Murray, Joseph C; Shuptrine, Casey W (2012) Antibody-based immunotherapy of cancer. Cell 148:1081-4|
|Ratushny, V; Pathak, H B; Beeharry, N et al. (2012) Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene 31:1217-27|
Showing the most recent 10 out of 42 publications